Original Article
Open Access
Protection against Endothelial Injury Mediates the Anti-thrombotic Effect of Danggui Buxue Decoction in a Rat Model of Cirrhotic Portal Vein Thrombosis
Yanan Guo, Sisi Dong, Meng Li, Yanyan Tao, Jing Lv, Chenghai Liu
Gastroenterology & Hepatology Research, Published online December 5, 2025. doi:10.14218/GHR.2025.00001
Abstract
PVT is a harmful event in cirrhosis, and the prevention and treatment of PVT are important in the management of cirrhosis and portal hypertension. The study aimed to observe the
[...] Read more.
PVT is a harmful event in cirrhosis, and the prevention and treatment of PVT are important in the management of cirrhosis and portal hypertension. The study aimed to observe the efficacy of Danggui Buxue Decoction (DBD) on portal vein thrombosis (PVT) in cirrhosis and to elucidate the related mechanism using a modified animal model.
A model of PVT in cirrhosis was established by partial portal vein ligation and intraperitoneal injection of CCl4 in rats, which showed obvious PVT with intra- and extravenous thrombosis as well as liver cirrhosis. Rats were randomly assigned into four groups and received intragastric administration of DBD (12 g/kg/day) or rivaroxaban (20 mg/kg/day) for 6 weeks.
DBD attenuated collagen deposition and reduced thrombus formation in model livers, increased portal vein blood flow, expanded the portal vein diameter, and reduced prothrombin time and international normalized ratio in the model rats. In addition, DBD reduced hepatic von Willebrand factor and plasminogen activator inhibitor-1 expression and increased hepatic fibrin degradation product content in the liver tissues of model rats.
We modified a model of cirrhotic PVT in rats and found that DBD had a good effect on PVT and liver fibrosis, with the mechanisms related to the enhancement of portal vein blood flow and the protection against endothelial cell injury.
Full article
Review Article
Open Access
Exploration of the Integrated Traditional Chinese and Western Medicine Treatment Model for Primary Liver Cancer Under the Guidance of the Green Treatment Concept of Tumor
Si-Qi Zhang, Bao-Ping Luo, Ya-Na Zhou, Yong Zhou, Kai-Wen Hu
Gastroenterology & Hepatology Research, Published online December 25, 2025. doi:10.14218/GHR.2025.00005
Abstract
Unlike the traditional staging treatment of tumors, the core of “Green Tumor Treatment” is to divide the treatment of tumors into three stages: Hegemony (directly targeting the
[...] Read more.
Unlike the traditional staging treatment of tumors, the core of “Green Tumor Treatment” is to divide the treatment of tumors into three stages: Hegemony (directly targeting the cancer focus), Kingship (supporting the body’s vital energy and eliminating pathogenic factors), and Imperialism (improving the internal environment), based on the urgency of the tumor and the patient’s physical condition. This approach guides the clinical treatment of tumors. Its treatment system incorporates all minimally invasive and low-damage treatment methods, combining internal and external treatments, traditional Chinese medicine and Western medicine, as well as local and systemic treatments. It aims to maximize treatment outcomes while ensuring the patient’s quality of life, which is highly consistent with the treatment goals for primary liver cancer. This review aims to explore the integrated Traditional Chinese and Western medicine treatment model for primary liver cancer under the guidance of the Green Tumor Treatment concept.
Full article
Review
Open Access
Progress of research on tetrahydrocurcumin against liver injury
Ke-Yu Chen, Shuang Luo, Yun-Teng Liu, Xue Wang, Jian-Bo Wang
Gastroenterology & Hepatology Research, Published online September 21, 2023. doi:10.53388/ghr2023-03-078
Abstract
Liver injury has become a serious liver disease worldwide, and its incidence is increasing year by year, bringing a serious health burden to people in all countries. Tetrahydrocurcumin
[...] Read more.
Liver injury has become a serious liver disease worldwide, and its incidence is increasing year by year, bringing a serious health burden to people in all countries. Tetrahydrocurcumin is an active metabolite of curcumin, which has pharmacological effects such as antioxidant, anti-inflammatory, inhibition of apoptosis, anti-tumor, and anti-aging, and it can inhibit apoptosis in liver cells under the state of hepatic injury and reduce the level of oxidative stress and inflammation in liver tissues through the signaling pathways such as MAPK, PI3K/Akt, PPAR, AMPK, and Nrf2 to prevent and control liver injury. The purpose of preventing and controlling liver injury can be achieved. The active structure, pharmacological effects and application of tetrahydrocurcumin in liver injury were summarized by reviewing domestic and international literature, with a view to providing reference for further research on tetrahydrocurcumin in the field of liver injury.
Full article